Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/26/2020 06/29/2020 06/30/2020 07/01/2020 07/02/2020 Date
29.98(c) 31.69(c) 26.95(c) 19.73(c) 21.45 Last
150 212 749 52 957 931 98 389 961 103 810 587 52 322 047 Volume
-4.06% +5.70% -14.96% -26.79% +8.72% Change
More quotes
Financials (USD)
Sales 2020 13,6 M - -
Net income 2020 -111 M - -
Net Debt 2020 - - -
P/E ratio 2020 -28,2x
Yield 2020 -
Sales 2021 485 M - -
Net income 2021 0,18 M - -
Net Debt 2021 - - -
P/E ratio 2021 15,4x
Yield 2021 -
Capitalization 3 119 M 3 119 M -
Capi. / Sales 2020 230x
Capi. / Sales 2021 6,43x
Nbr of Employees 190
Free-Float 97,5%
More Financials
Company
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target... 
More about the company
Surperformance© ratings of Inovio Pharmaceuticals, In
Trading Rating : Investor Rating :
More Ratings
Latest news on INOVIO PHARMACEUTICALS, IN
03:30pINOVIO PHARMACEUTICALS : Wall Street shifts bets to big pharma as COVID-19 vacci..
RE
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
07/01China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacity
RE
06/30Health Care Up As Sector Seen As Resilient In Covid Era -- Health Care Roundu..
DJ
06/30Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters
RE
06/30INOVIO PHARMACEUTICALS : Announces Positive Interim Phase 1 Data For INO-4800 Va..
PR
06/25INOVIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regul..
AQ
06/23INOVIO PHARMACEUTICALS : Receives $71 Million Contract From U.S. Department of D..
PR
06/04INOVIO PHARMACEUTICALS : and IVI Partner with Seoul National University Hospital..
PR
06/03INOVIO PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
05/27Moderna rally loses steam over COVID-19 vaccine worries
RE
05/26SHAREHOLDER ALERT : Robbins LLP Is Investigating the Officers and Directors of I..
BU
05/26INOVIO TO HOST WEBINAR "DNA MEDICINE : From COVID-19 to Cancer"
PR
05/20Inovio, Spotify rise; Urban Outfitters, Eaton Vance fall
AQ
05/20Covid-19 Researchers Find Clues on Coronavirus Immunity in Lab Animal Tests
DJ
More news
News in other languages on INOVIO PHARMACEUTICALS, IN
03:30pINOVIO PHARMACEUTICALS : Wall Street shifts bets to big pharma as COVID-19 vacci..
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
07/01BioNTech treibt Corona-Impfstoffprojekt nach positiven Daten voran
07/01China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacity
06/30Health Care Up As Sector Seen As Resilient In Covid Era -- Health Care Roundu..
More news
Stock Trading Strategies
INOVIO PHARMACEUTICALS, INC. - 05/22
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart INOVIO PHARMACEUTICALS, IN
Duration : Period :
Inovio Pharmaceuticals, In Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, IN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 20,86 $
Last Close Price 19,73 $
Spread / Highest target 128%
Spread / Average Target 5,71%
Spread / Lowest Target -59,5%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.497.88%3 119
LONZA GROUP42.13%39 473
CELLTRION, INC.70.44%33 100
SEATTLE GENETICS, INC.46.61%28 998
IQVIA HOLDINGS INC.-8.40%27 027
MODERNA, INC.214.88%23 948